[{"from": "human", "value": "What can you tell me about this molecule? [C][C][=C][N][=C][Branch2][Ring2][N][N][=C][Ring1][=Branch1][C][=C][N][C][C@@H1][Branch2][Ring1][=N][N][Branch1][O][C][=Branch1][C][=O][C][Ring1][#Branch1][=N][Ring1][#Branch2][C][C][=C][C][=Branch1][=Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][F][C][O][C][N][C][=C][C][=N][N][Ring1][Branch1][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, tizaterkib specifically targets, binds to and inhibits the activity of the serine/threonine-protein kinases ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells."}]